233 related articles for article (PubMed ID: 28336365)
21. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
22. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
23. Epithelial-mesenchymal transition increases during the progression of in situ to invasive basal-like breast cancer.
Choi Y; Lee HJ; Jang MH; Gwak JM; Lee KS; Kim EJ; Kim HJ; Lee HE; Park SY
Hum Pathol; 2013 Nov; 44(11):2581-9. PubMed ID: 24055090
[TBL] [Abstract][Full Text] [Related]
24. Breast cancer epithelial-to-mesenchymal transition: examining the functional consequences of plasticity.
Drasin DJ; Robin TP; Ford HL
Breast Cancer Res; 2011; 13(6):226. PubMed ID: 22078097
[TBL] [Abstract][Full Text] [Related]
25. Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer.
Gunasinghe NP; Wells A; Thompson EW; Hugo HJ
Cancer Metastasis Rev; 2012 Dec; 31(3-4):469-78. PubMed ID: 22729277
[TBL] [Abstract][Full Text] [Related]
26. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer.
Cai J; Tian AX; Wang QS; Kong PZ; Du X; Li XQ; Feng YM
Cancer Lett; 2015 Oct; 367(2):129-37. PubMed ID: 26210254
[TBL] [Abstract][Full Text] [Related]
27. MicroRNAs regulate the epithelial-mesenchymal transition and influence breast cancer invasion and metastasis.
Zhao M; Ang L; Huang J; Wang J
Tumour Biol; 2017 Feb; 39(2):1010428317691682. PubMed ID: 28222665
[TBL] [Abstract][Full Text] [Related]
28. Targeting EMT in cancer: opportunities for pharmacological intervention.
Davis FM; Stewart TA; Thompson EW; Monteith GR
Trends Pharmacol Sci; 2014 Sep; 35(9):479-88. PubMed ID: 25042456
[TBL] [Abstract][Full Text] [Related]
29. Epithelial-mesenchymal plasticity of breast cancer stem cells: implications for metastasis and therapeutic resistance.
Luo M; Brooks M; Wicha MS
Curr Pharm Des; 2015; 21(10):1301-10. PubMed ID: 25506895
[TBL] [Abstract][Full Text] [Related]
30. Epithelial-to-mesenchymal transition: what is the impact on breast cancer stem cells and drug resistance.
Mallini P; Lennard T; Kirby J; Meeson A
Cancer Treat Rev; 2014 Apr; 40(3):341-8. PubMed ID: 24090504
[TBL] [Abstract][Full Text] [Related]
31. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer-associated fibroblasts induce epithelial-to-mesenchymal transition in breast cancer cells.
Soon PS; Kim E; Pon CK; Gill AJ; Moore K; Spillane AJ; Benn DE; Baxter RC
Endocr Relat Cancer; 2013 Feb; 20(1):1-12. PubMed ID: 23111755
[TBL] [Abstract][Full Text] [Related]
33. Epithelial-Mesenchymal Plasticity in Cancer Progression and Metastasis.
Lu W; Kang Y
Dev Cell; 2019 May; 49(3):361-374. PubMed ID: 31063755
[TBL] [Abstract][Full Text] [Related]
34. The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis.
Meng F; Wu G
Cancer Metastasis Rev; 2012 Dec; 31(3-4):455-67. PubMed ID: 22733307
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic and metabolic regulation of breast cancer stem cells.
Liu HX; Li XL; Dong CF
J Zhejiang Univ Sci B; 2015 Jan; 16(1):10-7. PubMed ID: 25559951
[TBL] [Abstract][Full Text] [Related]
36. Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept.
Chua KN; Poon KL; Lim J; Sim WJ; Huang RY; Thiery JP
Adv Drug Deliv Rev; 2011 Jul; 63(8):558-67. PubMed ID: 21335038
[TBL] [Abstract][Full Text] [Related]
37. Overexpression of SDF-1 activates the NF-κB pathway to induce epithelial to mesenchymal transition and cancer stem cell-like phenotypes of breast cancer cells.
Kong L; Guo S; Liu C; Zhao Y; Feng C; Liu Y; Wang T; Li C
Int J Oncol; 2016 Mar; 48(3):1085-94. PubMed ID: 26782945
[TBL] [Abstract][Full Text] [Related]
38. Generation of MCF-7 cells with aggressive metastatic potential in vitro and in vivo.
Ziegler E; Hansen MT; Haase M; Emons G; Gründker C
Breast Cancer Res Treat; 2014 Nov; 148(2):269-77. PubMed ID: 25292421
[TBL] [Abstract][Full Text] [Related]
39. Epithelial-mesenchymal transition in breast cancer progression and metastasis.
Wang Y; Zhou BP
Chin J Cancer; 2011 Sep; 30(9):603-11. PubMed ID: 21880181
[TBL] [Abstract][Full Text] [Related]
40. 3,5,4'-Trimethoxystilbene, a natural methoxylated analog of resveratrol, inhibits breast cancer cell invasiveness by downregulation of PI3K/Akt and Wnt/β-catenin signaling cascades and reversal of epithelial-mesenchymal transition.
Tsai JH; Hsu LS; Lin CL; Hong HM; Pan MH; Way TD; Chen WJ
Toxicol Appl Pharmacol; 2013 Nov; 272(3):746-56. PubMed ID: 23921149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
